BP 897

Drug Profile

BP 897

Latest Information Update: 23 Mar 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bioprojet; University of Cambridge
  • Class Antiparkinsonians; Drug withdrawal therapies
  • Mechanism of Action Dopamine D3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cocaine abuse; Parkinson's disease

Most Recent Events

  • 23 Mar 2007 Discontinued - Phase-II for Cocaine abuse in France (unspecified route)
  • 23 Mar 2007 Discontinued - Phase-II for Parkinson's disease in France (unspecified route)
  • 07 Oct 2003 A preclinical study has been added to the Drug withdrawal pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top